Business News • PR NewsWire • Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

NORTH CHICAGO, Ill., June 12, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced updated results of a Phase 1b study that showed patients with relapsed/refractory chronic lymphocytic leukemia (CLL) taking venetoclax, an investigational...

View More : http://www.prnewswire.com/news-releases/phase-1b-study-of-investigational-treatment-venetoclax-with-rituximab-shows-clin...

Releted News by prnewswire

OpenTaste Launches An Online Platform That Reinvents The Food Supply Chain To Bring The Freshest, Highest Quality Produce Directly To Consumers

Sunsweet Growers Official Nutrition Supporter Of World Osteoporosis Day

Fall In Love With Lobster This Summer: Uno Pizzeria & Grill Introduces New Lobster Dishes And Other Summertime Favorites

New Data Show CMS Competitive Bidding Program Coincided with Increased Hospitalizations and Death Among Medicare Beneficiaries with Diabetes

SBA Consolidates Disaster Loan Outreach Centers in Baltimore